ABSTRACT BACKGROUND
RESULTS

The prevalence of NAFLD among diabetes in our study was found to be 26%.It was found to be more common in the fourth decade of life with equal distribution among men and women. Among the patients with NAFLD 53.6% were associated with hypertension (HTN), 75% with dyslipidemia and 19% with BMI >19%.38% of the patients with NAFLD were found to have elevated alaninetransaminase (ALT) and 26% hadelevated aspartate transaminase (AST). 73% of the NAFLD patients had elevated cholesterol.26% of the patients in our study were found to have sonological features suggestive of NAFLD. CONCLUSION This study demonstrates and clinically correlates the cluster of abnormalities /risk factors like hypertension, obesity, duration of diabetes with NAFLD.The implication of the study is that diabetics are at a higher risk of developing NAFLD and its related complications.
1.INTRODUCTION
NAFLD is the most common liver disease and the third leading indication for liver transplantation 1 . The prevalence of NAFLD has been reported to be 15-30% in the general population and in T2 DM population, the prevalence is 70-75% 2 . NAFLD has been proposed as one of the components of metabolic syndrome (MS) 4 . It has been found to be a composite of confirmed cases with central obesity, T2DM and dyslipidemia. Studies have shown the major role of obesity and insulin resistance in NAFLD 5 . However, regardless of BMI, the presence of T2 DM significantly increases the risk and severity of NAFLD 6 . Only recently liver disease has been recognized as a major complication of T2 DM with increased mortality rates for cirrhosis greater than that
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for cardiovascular disease 8 . Insulin resistance plays a central pathogenic role in both T2 DM and NAFLD with the latter being considered as the hepatic manifestation of the MS 9 .
OBJECTIVE OF THE STUDY
To study the clinicopathological profile of hepatic involvement in T2 DM and correlate between them.
REVIEW OF LITERATURE
NAFLD was practically unheard a few years ago, but is now considered one of the most commonliver disorders in the world 8 .It may be the most common cause of liverenzyme elevation in adults as well as one of the leading cause for cirrhosis in the world.The prevalence of NAFLD has increased in joint with the epidemics of obesity and T2 DM, which are the major risk factors for NAFLD 10 . Whereas the association of T2 DM with microvascularcomplications and macro-vascular disease is well established.
Theassociation of T2 DM with NAFLD is a recently recognized entity and less well known 10 .There is evidence that patients with NAFLD who have T2 DM particularly at a high risk of developing cirrhosis compared with those who donot have diabetes. Although cardiovascular disease is the majorcause of excess morbidity and mortality inT2 DM, liver failuremay also be a threat to patients with T2 DM 12 . NAFLD is characterized by fatty infiltration of the liver, mostly in the form of triglycerides, which exceeds 5% of the liver weight.NAFLD is histologically similar to alcoholic liver disease (ALD), but itoccurs in the absence of excessive alcohol consumption and is not dueto other identifiable causes of fatty liver 13 .
CONDITIONS ASSOCIATED WITH FATTY LIVER DISEASE
25
 Diabetes mellitus
NAFLD represents a spectrum of clinical-pathologicalfeatures ranging from simplesteatosis, which is characterized by fatty infiltration only to non-alcoholic steatohepatitis (NASH), which is characterized by inflammation and hepatocellular injury with orwithout fibrosis and cirrhosis. Most with NAFLD have an increase inliver fat content alone and some developNASH that can progress to cirrhosis.
PREVALENCE
Data from the Dallas HeartStudy suggested that about one-third of the population of Dallas County, Texas had hepatic steatosis 25 . This study used proton magneticresonance spectroscopy (MRS) to measure liver fat and definedsteatosis as hepatic triglyceride content >5.5%. Having diabetes carries an even higher risk. Sixty-two per cent ofsubjects in the Dallas Heart Study who had either known diabetes had hepatic steatosis.
As most who have NAFLD have no specific signs or symptoms, it goes unnoticed. In clinical practice,elevated aminotransferase levels, especially ALT, are considered a marker for liver disease 17 . However, manypatients who have NAFLD do not have elevated levels. In the DallasHeart Study, 79% of those with hepatic steatosis had normal ALTlevels. Making thematter of establishing the diagnosis of NAFLD even more complicatedis that aminotransferase levels do not necessarily correlate with theseverity of NAFLD. ALT levels may be normal in the presence ofadvanced fibrosis or cirrhosis 19 . Thus, a normal ALT does not excludesteatosis and does not ensure the absence of underlying advanced liverdisease 21 .
Therefore, since non-invasive methods of detection were used in these epidemiological studies, the prevalence of pure steatosisversus more advanced stages of disease such as steatohepatitis,fibrosis or cirrhosis is unknown 28 .
SYMPTOMS
As with many other types of CLD, mostpatients with NAFLD (48-100%) are asymptomatic.The liver disease is often discovered incidentallyduring routine laboratory examination when a hepaticpanel reveals an elevated 22 .
SIGNS
There are no pathognomonic signs of NAFLD. Obesity is the most common abnormality on physical examination, occurring in 30-100% of patients in various cross-sectionalstudies 26 . Hepatomegaly has been reported in up to 75% of patients in several studies .The prevalence of hepatomegaly may increase to 95%when assessed by USG. Of the various stigmata, spidernevi and palmar erythema are the most common .Muscle wasting may occur as liver disease becomes moreadvanced but is often underestimated due to edema and preexisting obesity 27 .
LABORATORY FINDINGS
Mild to moderate elevation of serum aminotransferases (ALT and AST) is the most common and often the only laboratory abnormality found in patients with NAFLD 29 .There is no significant correlation between the degree of serum aminotransferase elevation and the histologic severity of hepatic inflammation or fibrosis . Unlike those with alcohol-induced steatohepatitis, who typically manifest disproportionate increases in the AST level relative to the ALT level, patients with NAFLD usually haven AST/ALT ratio <1 .
The AST/ALT ratiotends to increase with the development of cirrhosis, thuslosing its diagnostic accuracy. Serum alkaline phosphatase (ALP) may also be slightly elevated in aboutone-third of patients. Hyperbilirubinemia, hypo-albuminemia, and prolongation of the prothrombin time (PT) are noted infrequently and generally only seen once liver failure has become established. Elevated serum lipid profiles and glucose concentrations are also common in NAFLD patients, reported in 25 to 75% of cases.
A small percentage of patients with NAFLD may have a low-titer (≤1:320) antinuclear antibody (ANA) positivity 25 . The role of iron in the pathogenesis ofNAFLD remains controversial.
It is important to exclude secondary causes of hepatic fat so that the diagnosis of primary NAFLD can be made reliably. Hepatitis C (HCV) and alcoholic liver disease are particularly important because of the high prevalence of these two hepatotoxic agents 28 .HCVcan cause histologic changes that closely resemble NAFLD, thus serologic testing to exclude viral hepatitis has become a pre-requisite for the diagnosis of NAFLD 29 .
By its very definition, the diagnosis of NAFLD cannot be made in the settingof excessive alcohol consumption. However, there is noconsensus among investigators concerning what is an excessiveamount of alcohol and thus there are no published and universally accepted threshold levels. It is generally believed that a fatty liver does not develop with alcohol.
IMAGING
Several noninvasive imaging techniques, including USG, computed tomography (CT), and magnetic resonance imaging (MRI), can identify hepatic steatosis and have been advocated as diagnostic tests for NAFLD 26 . USG is the most commonly used. The sonographicfindings of diffuse fatty change include a diffuse Hyperechoic echotexture (bright liver), increased liver echotexture compared with the kidneys, vascular blurring and deep attenuation. Fatty infiltration of the liver produces a low-density hepatic parenchyma on CT scanning. In a direct comparison of CT with USG, USG was found to be more sensitive in detecting fatty change. However, when fatty change is patchy or focal, CT scan and MRI are superior to USG. Also, when a semi quantitative assessment is required or when multiple comparative studies are planned over time, CT is superior to US.
MRS is a newer innovative radiologic technique allowing one to examine the resonance frequencies of all proton species within a region of interest and is being investigated as a means of obtaining a more quantitative assessment of fatty liver infiltration. Despite the utility of these imaging modalities in the diagnosis of diffuse fatty disorders of the liver, none is sufficiently sensitive to detect hepatic inflammation, fibrosis or cirrhosis. 
Study On Non Alcoholic Fatty Liver Diseases in Type 2 Diabetes Mellitus With Clinical Correlation
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In a prospective study evaluating therole of different radiological modalities in establishing thediagnosis of NASH, neither USG, CT, nor MRI was able todetect the presence of hepatocyte ballooning, Mallory'shyaline, or fibrosis, which are all important features in thediagnosis of NASH. With the inability to distinguishsimple steatosis from steatohepatitis and stage the severityof injury, liver biopsy remains the best diagnostic test for NASH 31 .
LIVER HISTOLOGY
The lack of effectivemedical therapy for NAFLD and risks associated withbiopsy are arguments proposed against obtaining tissue sampling 30 . Nevertheless, liver biopsy is the only accuratemethod for the diagnosis ofNASHand the only meansto determine the severity of liver damage and long-term prognosis.
The histological features of NAFLD are indistinguishable from those of alcohol-induced liver disease. There are two lesions associated with NAFLD:
And varying amounts of cytological ballooning and spotty necrosis, scattered mixed Neutrophilic-lymphocytic inflammation, glycogen nuclei, Mallory's hyaline, and per sinusoidal fibrosis (NASH). All of the features of steatohepatitis are not present in every instance of steatohepatitis. The severity of steatosis can be graded on the basis of the extent of involved parenchyma.
Given the association of NAFLD with metabolic syndrome (MS), obesity and T2 DM the prevalence of NAFLD and NASH are increasing. Within the NAFLD spectrum, only patients with histologically proven NASH develop progressive liver disease. Progression seems more likely in the setting of diabetes, insulin resistance and other pre-existing conditions.
Hence it is reasonable to expect that early diagnosis of NAFLD and early intervention which would prevent progression to more serious stages
METHODOLOGY SOURCE OF DATA
The data was collected from both outpatients and inpatients in Father Muller's Medical College Hospital from 1st August 2013 to 1st August 2014.
METHOD OF DATA COLLECTION STUDY DESIGN
The study is a descriptive prospective study of the patients in Father Muller's Medical College with T2 DM. The study will includes 100 patients with equal sex ratio, diagnosed with T2 DM.These patients was evaluated by a detailed history including the age , sex ,location, duration of diabetes , history of previous illness , medication they were currently taking. Clinical examination includes anthropometric measurements including height and weight and thus the BMI, signs of insulin resistance-central obesity, xanthelesma, acanthosisnigricans .Investigations include abdominal USG for fatty liver, HbA1c, LFT and lipid profile .Results will then be analyzed and compared.
INCLUSION CRITERIA
(1) Known cases of T2 DM ( > 3 years) patients of both sexes between the age group of 25 to 80. EXCLUSION CRITERIA (1) Known history of chronic viral hepatitis (2) Individuals with alcohol consumption (3)
History of drug intake that can cause fatty liver. (4) Patients with nephropathy. (5) Patients in congestive cardiac failure (CCF). (6) Patients on insulin.
DATA ANALYSIS:
Data was analyzed by frequency,percentage, mean and standard deviation. 
RESULTS PREVALENCE OF NAFLD
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The prevalence of NAFLD was found to be higher in the fourth decade
SEX DISTRIBUTION SEX * USG-FATTY LIVER Cross tabulation
The disease incidence was found to be equal among both males and females. Page 106
DURATION OF DIABETES
The prevalence of NAFLD was found to be more among the patients with more than 2 year duration of diabetes Page 108
SIGNS AND SYMPTOMS
ASSOCIATION WITH HYPERTENSION
In our study 28% of the total cases included were hypertensives. Out of which 53.6% were found to be associated with NAFLD. 
ASSOCIATION WITH DYSLIPIDEMIA
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In our study, 12% of the total cases included were found to have dyslipidemia. Out of the dyslipidemics, 75% were found to have fatty liver.
ASSOCIATION WITH BODY MASS INDEX
In our study, 34% of the total cases were found to have BMI > 
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38% of the patients with NAFLD were found to have elevated SGPT and 26% of the patients were found to have elevated SGOT.
DISCUSSION:
NAFLD represents a group of disease, characterized histologically by excessive accumulation of hepatic fat in the absence of significant alcohol consumption; with or without inflammation, varying degree of fibrosis and cirrhosis 32 . Our study on NAFLD in patients diagnosed with T2 DM was conducted on 100 inpatients and outpatients of Father Muller Medical College.
PREVALENCE OF NAFLD IN TYPE 2 DIABETES MELLITUS:
The majority of the studies on NAFLD in T2 DM population are based on histological evidence of steatosis. There are also several studies based on fatty infiltration proven by imaging. 
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However there are only very few studies involving the clinical correlation with NAFLD with biochemical as well as sonological evidence.
The overall prevalence of NAFLD in T2DM in this study was found to be 26%, which is lower than the prevalence rates in different studies conducted in India-Kalra S et al which was 56.5% and Mohan et al which was 54.5% 41 .
However the prevalence rates were found to be higher than the prevalence rates of 12.5% and 20 %described by AgalS etal 44 .
One of the studies of NAFLD in T2 DM based on histological evidence by Banerjee S et al showed a much higher prevalence rate of 87%.
Based on the type of study, the prevalence rates were much higher in those which had histological evidence for NAFLD in comparison to those which were conducted based on biochemical and sonologicalevidence .
AGE DISTRIBUTION OF NAFLD AMONG DIABETICS
Studies in India have revealed the mean age group of patients with NAFLD in diabetes to be between 40 to 50 years.
In this study, the disease occurrence was found to be predominantly in thefourth decade.
In a similar study done in India by Kalra S et al, the prevalence of the disease was found to higher with increasing age and commonest in the fifth decade 32 .
A study conducted in Chennai by Vishwanathan V et al was also found to have a predominant incidence of fatty liver with diabetes in the sixth decade of life 41 .
SEX DISTRIBUTION OF NAFLD AMONG DIABETICS
Most of the studies in India have shown a higher prevalence of NAFLD among males than female population 46 .
In our study the disease incidence was equally distributed among male and femalepopulation.However a study by Kalra S et al revealed higher prevalence rate of disease among females (60%) than in male (53.4%) population 41 .
ASSOCOATION OF HYPERTENSION, DYSLIPIDEMIA AND OBESITY WITH NAFLD
There is an important and well established clinical association between NAFLD and HTN, diabetes, dyslipidemia, obesity. Page 114
ASSOCOATION WITH HYPERTENSION
The association of NAFLD with HTN is well documented; systolic being more commonly associated in a study by BellentaniS et al 44 .
In a study by Banerjee et al , both increased systolic and diastolic blood pressure were significantly associated with NAFLD ,more so with diastolic BP 43 .
In our study 28% of the total cases included were hypertensives. Out of which 53.6% were found to be associated with NAFLD.
In a study conducted by Kalra S et al out of the 557 hypertensive patients enrolled, 336 were found to be associated with NAFLD 45 .
In a study by Viswanathan et al, 64.7% of the hypertensives included in the study were found to be associated with NAFLD 41 . 
ASSOCIATION WITH DYSLIPIDEMIA
In our study, 12% of the total cases included were found to have dyslipidemia. Out of the dyslipidemics , 75% were found to have fatty liver.
In a study by Kalra S et al, outof 485 patients with dyslipidemia , 311 (59.6%) were found to have NAFLD 41 .
In a study by Viswanathan et al , 85.3% of the subjects with dyslipidemia were found to be associated with NAFLD 46 . 
STUDY
ASSOCIATION WITH BMI
Obesity in particular central obesity has been described as one of the strongest risk factors NAFLD and fibrosis 42 .
In our study, 34% of the total cases were found to have BMI > 25 Kg/m 2. . Out of which 19% were found to have fatty liver.
In a study conducted in Kalra S et al, 53.6% of those patients with obesity enrolled in the study were found to be associated with fatty liver 42 .
In a study by Viswanathan et al 27.6% of the patients with BMI >25% enrolled were found to be associated with NAFLD 46 . Page 115
ASSOCIATION WITH THE DURATION OF TYPE 2 DIABETES MELLITUS
The prevalence of NAFLD was also noticed to bedirectly proportional to the duration of diabetes 44 . In this study, the group of patients with more than 5 year duration of diabetes were found to have an incidence of 46.2%. A declining trend in the incidence of NAFLD was noted with a decline in the duration of diabetes. 38.5% and 15.4% were the incidence rates in the groups with duration of diabetes 3to 4 years and 1 to 2 years respectively.
ASSOCIATION WITH LIVER ENZYMES
Arruda MJ et al , in his study produces enough evidence to suggest that mild elevation in the liver enzymes maybe a marker for significant liver disease 40 .
In our study, mean ALT levels were found to be higher than AST levels.
38% of the patients with NAFLD were found to have elevated ALT and 26% of the patients were found to have elevated AST.
In a study by Kalra S et al , conducted across 101 centers in India , the mean ALT was found to be higher than mean AST 41 .34.9 % of the patients with NAFLD were found to have at least one abnormal aminotransferase level out of which 19% had elevation in the ALT and 15.9% had elevation in the AST levels. 65.1% of the patient was found to have elevation of both ALT and AST.
ALT AST PRESENT STUDY 38% 26% Kalra S et al 19% 15.9%
However there have also been studies where there has not been significant correlation between the liver enzymes and NAFLD.
In Dallas heart study, 79% of those with hepatic steatosis had normal ALT levels. ALT levels may be normal in the presence of advanced fibrosis or cirrhosis.
NAFLD AND ULTRASONOGRAPHY
USG is by far the commonest method of diagnosing NAFLD in clinical practice. The sensitivity of diagnosing NAFLD sonologically is found to be 83% 45 .
In our study, 26% of the patients were found to be associated with increased echogenicity of the liver suggestive of fatty liver.
Other noninvasive techniques including CT and MRI can identify hepatic steatosis. Of these MRI appears to be most promising, because its results correlate well with the degree of histologic steatosis.
NAFLD AND HISTOLOGY
The gold standard for diagnosing NAFLD is clinicopathological correlation with confirmation of steatosis by biopsy 42 . Liver biopsy is the only test which can reliably identify and quantify hepatic necrosis, inflammation and fibrosis. Hence it plays a very important role in staging the disease.
Recommending liver biopsy for everyone subjected of having NAFLD would not be practical. Arguments against a biopsy in everyone include the high prevalence of NAFLD, cost and potential risks with the procedure. 
SUMMARY
